Aeterna Zentaris: Article on Phase 2 Results for Zoptarelin Doxorubicin in Endometrial Cancer Published in the International Journal of Gynecological Cancer

About this update from Cosciens Biopharma Inc.

[{"type":"text","content":"\n\n\nQUÉBEC CITY, Feb. 4, 2014 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS) (TSX: AEZ) (the \"Company\") today announced that an article on\n Phase 2 results for zoptarelin doxorubicin (AEZS-108) in endometrial\n cancer has been published in the February issue of the  International Journal of Gynecological Cancer. Zoptarelin doxorubicin, is the Company's cytotoxic peptide conjugate\n which specifically targets luteinizing hormone-releasing hormone\n (\"LHRH\") receptors. The article, \"Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in\n Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH\n Receptors: A Multicenter Phase 2 Trial (AGO-GYN5)\", Emons G., Gorchev G., Harter P., Wimberger P., Stähle A., Hanker L.,\n Hilpert F., Beckmann M.W., Dall P., Gründker C., Sindermann H., Sehouli\n J., outlines results of this study which had been previously presented\n at the European Society of Gynaecological Oncology's (\"ESGO\") annual\n meeting in September 2011. The article is currently available at this link.\n\n\n\"These encouraging results were the basis for our current Phase 3 ZoptEC\n (Zoptarelin doxorubicin in Endometrial Cancer) trial in women with\n advanced, recurrent or metastatic endometrial cancer who have\n progressed and have received one chemotherapeutic regimen with platinum\n and taxane\", stated David Dodd, President and CEO of Aeterna Zentaris.\n \"This compound's innovative targeted approach potentially offers a much\n needed novel treatment option for women with endometrial cancer and\n could provide the Company with a significant market opportunity.\"\n\n\nPhase 2 Study Results and Conclusion\n\n\nForty-four patients were entered onto the study at 8 centers in Germany\n and 3 centers in Bulgaria. Forty-three of these patients were eligible.\n Two patients had a complete remission (5%) and 8 achieved a partial\n remission (18%). Stable disease for at least 6 weeks was observed in\n 44%. The median time to progression (TTP) was 7 months and median\n overall survival (OS) was 15 months. The most frequently reported grade\n 3 or 4 adverse effects were neutropenia (12%) and leucopenia (9%).\n\n\nData showed that zoptarelin doxorubicin has clinically meaningful\n activity with low toxicity in women with advanced or recurrent LHRH\n receptor positive ...

More updates from Cosciens Biopharma Inc.